Lynk Pharmaceuticals completes patient enrollment in Phase III trial of Zemprocitinib for ankylosing spondylitis, advancing a potential new autoimmune therapy
Executive summary: Lynk Pharmaceuticals completed patient enrollment in its Phase III clinical trial evaluating Zemprocitinib for ankylosing spondylitis. Reaching full enrollment is a critical precondition for obtaining topline efficacy and safety results, which could support a future NDA/BLA filing and influence Lynk’s valuation in the autoimmune disease space.
Who is involved: Lynk Pharmaceuticals (sponsor), clinical trial sites in China, the United States and other regions, and patients with ankylosing spondylitis.
Likely next: The company will now proceed to data lock, analysis, and announcement of topline results, expected within the next 6‑9 months, followed by potential regulatory interactions if the trial meets its endpoints.
The company announced that enrollment for its pivotal Phase III study of Zemprocitinib, an oral selective TYK2 inhibitor, has been finished. This milestone moves the asset closer to topline data readout and a possible regulatory submission. While the announcement is positive for Lynk’s pipeline, the ultimate commercial success will depend on the trial’s efficacy and safety outcomes versus established biologics in the ankylosing spondylitis market.
Timeline
- — Lynk Pharmaceuticals Announces Completion of Patient Enrollment in Phase III Clinical Trial of Zemprocitinib for Ankylosing Spondylitis (PR Newswire)
- — Kelun-Biotech Announces Phase III Study of Sacituzumab Tirumotecan (sac-TMT) in Combination with Pembrolizumab as First-Line Treatment for PD-L1-Negative Non-Squamous NSCLC (PR Newswire)
Analysis — what this means
Sectors affected
- ankylosing spondylitis therapeutics
- immunology
- biotech
Regulatory implications
- Positive Phase III data could trigger NDA submission to FDA and EMA for Zemprocitinib
Key entities
Sources
Open the full interactive case file on Beyond →
INTELLIGENCE
Social Pulse
AI estimate · not scraped